Chugai Pharmaceutical Co Ltd (OTCPK:CHGCF)
$ 43.78 -3.2505 (-6.91%) Market Cap: 73.00 Bil Enterprise Value: 73.11 Bil PE Ratio: 27.66 PB Ratio: 6.65 GF Score: 81/100

Chugai Pharmaceutical Co Ltd Information Meeting on Polivy Transcript

Jun 03, 2021 / 04:30AM GMT
Release Date Price: $40.4
Takaki Koga

I am Takaki Koga, Polivy Lifecycle Leader at Chugai Pharmaceutical Company. Today, I will give you an overview of what Polivy is and then ask Dr. Izutsu to make his presentation.

The name of the product is Polivy Intravenous Infusion, 30 milligram or 140 milligrams, and the generic name is polatuzumab vedotin, genetical recombination. It's indications are relapsed or refractory diffuse large B-cell lymphoma, but the name of the disease is a bit long. And so I'd like to use the English abbreviation, DLBCL. The name Polivy has been coined with Po coming from its generic name, polatuzumab vedotin, liv standing for life and y derived from the symbol for an antibody as it is an antibody drug conjugate. Thus, its English name is Polivy and Japanese name, Polivy.

On development history, in overseas, development was started by Roche in 2011. In Japan, a Phase I study was started in 2014. And in the same year in overseas, a global Phase Ib/II study was started for second-line treatment of patients with relapsed or refractory follicular lymphoma, which includes those with DLBCL. This study

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot